How Long Do You Take GLP-1 for Weight Loss? The Data
In this guide
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.
How long do you take GLP-1 for weight loss? The FDA labels for Wegovy and Zepbound do not give an end date. They describe these medicines as a way to reduce excess body weight and maintain that reduction long term. The trials ran from 68 weeks to about 4 years, and in the studies that stopped treatment, most people regained much of the weight they had lost. That is why many experts describe obesity treatment as ongoing. How long you take a medicine is a decision for you and your prescriber, based on your health, goals and side effects.
About Dosinha: a shot log, reminders, injection-site rotation, weight and water are free forever. See what is free and what Pro adds.
Key points
- The Wegovy and Zepbound labels describe long-term weight maintenance and set no stop date.
- Trials followed people on treatment for 68 weeks up to about 4 years, with weight loss sustained while treatment continued.
- In withdrawal trials, people switched to placebo regained a large share of the weight they had lost within a year.
- No trial tells you how long you personally should stay on a medicine. Your prescriber decides with you.
For how fast weight changed during those trials, start with our pillar on GLP-1 average weight loss per week.
What the labels say about duration
According to the Wegovy prescribing information, the injection is indicated with a reduced-calorie diet and more physical activity “to reduce excess body weight and maintain weight reduction long term” in adults and children 12 and older with obesity, and adults with overweight plus a weight-related condition. The Zepbound label uses the same long-term wording for adults.
Neither label gives a fixed number of weeks or months. Both describe a starting dose, step-ups and a maintenance dose, and the Zepbound label calls its maintenance doses the doses for “weight reduction and long-term maintenance.” Your prescriber and pharmacist set your plan.
The labels do name safety situations for stopping, such as suspected pancreatitis, a serious allergic reaction or planned pregnancy. These are safety rules, not a treatment length.
How long people stayed on treatment in trials
| Trial | Population | How long |
|---|---|---|
| STEP 1, semaglutide 2.4 mg | 1,961 adults without diabetes | 68 weeks |
| SURMOUNT-1, tirzepatide | 2,539 adults without diabetes | 72 weeks |
| STEP 5, semaglutide 2.4 mg | 304 adults without diabetes | 104 weeks |
| SELECT, semaglutide 2.4 mg | 17,604 adults with heart disease and no diabetes | Mean exposure 34.2 months, follow-up 39.8 months |
In STEP 5, mean weight change at two years was 15.2% on semaglutide versus 2.6% on placebo, and the authors describe the loss as plateauing after about week 60 and then being maintained. In a SELECT analysis, weight loss continued over 65 weeks and was sustained for up to 4 years, with a mean change at 208 weeks of 10.2% on semaglutide versus 1.5% on placebo. SELECT enrolled an older group with existing heart disease, so its numbers differ from STEP 1. The 2025 joint nutrition advisory led by Mozaffarian adds that with continued use, weight reduction has been sustained for at least 4 years.
What happened when trials stopped the medicine
Three studies looked at what happened after the medicine stopped:
| Trial | What was compared | Result |
|---|---|---|
| STEP 4, semaglutide 2.4 mg | After 20 weeks on semaglutide, 803 adults continued or switched to placebo for 48 weeks | Continued: down 7.9% more. Switched: up 6.9% |
| SURMOUNT-4, tirzepatide | After 36 weeks on tirzepatide, 670 adults continued or switched to placebo for 52 weeks | Continued: down 5.5% more. Switched: up 14.0% |
| STEP 1 extension, semaglutide 2.4 mg | 327 adults followed for a year after all treatment stopped at week 68 | Regained about two-thirds of the weight lost |
The STEP 1 extension authors wrote that their findings confirm obesity is chronic and suggest ongoing treatment is needed to keep the improvements in weight and health. They also report that most of the cardiometabolic improvements seen on semaglutide moved back toward baseline after stopping. For the full numbers, see what happens when you stop a GLP-1.
These are averages, and the trials stopped treatment outright. They did not test tapering. If you are weighing that question, stopping a GLP-1: cold turkey or taper covers what the labels and studies do and do not say.
In real life, many people stop early
The 2025 advisory reports that most people prescribed a GLP-1 for obesity stop within a year, with published discontinuation rates of 50% to 67% at 1 year and 85% at 2 years. It lists side effects, cost, variable results and personal preference as possible reasons, and notes low awareness that long-term use may be needed after a weight goal or a plateau is reached. If you are thinking about stopping for any of these reasons, tell your prescriber. There may be options you have not discussed.
Breaks and restarting
The Wegovy label says that if 2 or more doses in a row are missed, the dose escalation should be restarted at a lower dose to reduce stomach side effects. The Wegovy Medication Guide tells patients who miss 2 or more weeks to contact their healthcare provider about how to restart. Do not restart at your old dose on your own. Your prescriber and pharmacist set your plan.
When to call a clinician
Call your prescriber if you want to stop, if you already stopped, or if you are having side effects that make you want to stop.
When to call: severe stomach pain that will not go away, with or without vomiting, sometimes spreading to the back. Pain in the upper stomach with fever, yellow skin or eyes, or clay-colored stools. Nausea, vomiting or diarrhea that does not go away. Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing: get medical help right away.
These come from the Wegovy Medication Guide and the Zepbound label. The list is not complete.
Frequently asked questions
How long can you take a GLP-1 for weight loss?
The Wegovy and Zepbound labels describe long-term weight maintenance and do not set a maximum length. Trials followed people for up to about 4 years. How long is right for you is a decision with your prescriber.
Do you have to take a GLP-1 forever?
No label says forever, and no label says when to stop. In withdrawal trials, people who switched to placebo regained much of their lost weight within a year, which is why many experts describe obesity treatment as long term.
What happens if I stop after reaching my goal weight?
In SURMOUNT-4, adults who stopped tirzepatide after 36 weeks regained a mean 14.0% of body weight over the next 52 weeks. In the STEP 1 extension, people regained about two-thirds of their loss in a year. Talk to your prescriber before you stop.
Can you take a break from a GLP-1?
Ask your prescriber first. The Wegovy label says that after 2 or more missed doses in a row, the dose escalation is restarted at a lower dose to reduce stomach side effects.
Keep your own record
Long-term treatment is easier to review when you have the history in one place. Dosinha’s free shot log, reminders and weight log help you keep that record, and the side-effect check-in helps you notice patterns to share with your prescriber. The app does not tell you how long to take anything. Try the free tools. Related: GLP-1 weight loss without diabetes, plateau on GLP-1 and how to maintain weight after stopping.
Sources
- DailyMed. Wegovy prescribing information and Zepbound prescribing information. Labels posted 2026.
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 2022.
- Ryan DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 2024.
- Rubino D, et al. Continued weekly semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 2021. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity, 2025.
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.